AUTHORS
Sagar Munjal, MD, MS, Preethi Prasad2, Yi-Bin Chen, MD,MS3, Monzr M. M Al Malki, MD4
AFFILIATIONS
1 OSSIUM HEALTH, SAN FRANSISCO, California, United States
2 OSSIUM HEALTH, SAN FRANSISCO, California, United States
3 Massachusetts General Hospital, Boston, United States
4 City of Hope, Durate, United States
ABSTRACT
Background and Significance:
Allogeneic hematopoietic cell transplantation (alloHCT) offers a potentially curative treatment for hematologic malignancies. Cryopreserved, 4-8/8 HLA-matched hematopoietic progenitor cells (HPCs) harvested from the vertebral bodies of deceased organ donors (aged 7–55 years) provide a readily available, off-the-shelf option for patients with limited donor availability or in certain emergency situations. Initial data from the HOPE Expanded Access Program (NCT07145411) and the PRESERVE-I clinical trial (NCT05589896) have helped establish the safety profile of cryopreserved HPCs from deceased donors. In this trial, we seek to establish the efficacy, tolerability, and safety of partially to fully HLA-matched allogeneic cryopreserved deceased-donor bone marrow transplantation compared with living-donor transplantation.
Study Design and Methods:
This is a multicenter, open-label prospective study evaluating the efficacy, tolerability, and safety of partially to fully HLA-matched allogeneic cryopreserved deceased-donor bone marrow transplantation and living-donor transplantation in patients with hematologic malignancies (NCT07710781). Eligible patients are aged ≥12 and ≤80 years, without any prior allogeneic transplant, diagnosed with acute leukemia (acute lymphoblastic leukemia, acute myeloid leukemia, acute biphenotypic leukemia, or acute undifferentiated leukemia), myelodysplastic syndrome (MDS) without fibrosis, or chronic leukemia (CLL, CML), and in first remission or beyond with ≤5% marrow blasts, no circulating blasts, and no extramedullary disease. Patients must have a KPS ≥70% (MAC) or ≥60% (MAC), an HCT-CI ≤5, adequate organ function, absence of donor-specific antibodies, and no active uncontrolled infection. Three hundred patients (n=300) will be enrolled across three arms: the experimental arm is cryopreserved deceased-donor bone marrow transplantation (n=100), and the comparator arms are living haploidentical-related peripheral blood stem cell transplantation (n=100) and living mismatched-unrelated-donor peripheral blood stem cell transplantation (n=100). All patients will be followed for up to two years post-transplant. Patients will be enrolled in blocks of three, with one patient allocated to each arm per block; donor allocation within each block will be determined by the treating physician's clinical judgment, since a randomized controlled trial would not be ethical in this population. A new block opens once enrollment in the previous block is complete. Descriptive statistics will be used to summarize the characteristics of the study populations, treatment, and outcomes. Interim descriptive statistics will be summarized after 20 patients, and again after 50 patients, complete Day 30, Day 100, and Day 365 post-transplant assessments.
To our knowledge, this is the first prospective study to establish evidence-based donor selection using a novel design in stem cell transplantation, in which donor allocation within each block is determined by the treating physician rather than by randomization. Opening a new block at the same site only after the previous block's enrollment is complete helps control for confounding across the three arms. This will also be the largest prospective study to date of mismatched unrelated donor for cryopreserved deceased-donor bone marrow obtained from spine transplantation with two living-donor PBSC comparator arms.
DISCLOSURES
Sagar Munjal, MD, MS: Ossium health - Current equity holder in private company; Ossium health - Current Employment